Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anatara Lifesciences Ltd (ANR.AX)
Adelaide, VIC, AU
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.11% | +11.11% | +11.11% | -9.09% | -16.67% | -28.57% | +100.00% | -64.49% | -93.72% | -99.13% | -97.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+50.5% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+2.1% Q4'25: +61.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-140.8%
-
EBIT margin Biotechnology: +0.0%-201.8%
-
ROIC Biotechnology: -16.1%-232.4% Q4'25: -4,563.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+36.5% Q4'25: +92.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.21× Q4'25: 0.00× (vs Q4'23)
| Metric |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.45M
est: 1.00M (+144.8%)
|
2.85M
est: 1.75M (+63.1%)
|
6.5K
est: 800.0K (-99.2%)
|
663.4K
est: 1.70M (-61.0%)
|
—
est: 3.40M (-100.0%)
|
—
est: 6.00M (-100.0%)
|
—
est: 11.50M (-100.0%)
|
—
est: 24.70M (-100.0%)
|
644.0K
est: 35.90M (-98.2%)
|
| EBITDA |
-1.23M
est: 200.0K (-713.1%)
|
-4.22M
est: -1.10M (-283.7%)
|
-4.71M
est: -798.4K (-490.0%)
|
-3.69M
est: -7.34M (+49.8%)
|
-4.01M
est: -3.44M (-16.5%)
|
-3.01M
est: -1.49M (-102.0%)
|
-2.97M
est: 2.30M (-229.3%)
|
-3.21M
est: 4.94M (-165.0%)
|
-1.46M
est: 7.18M (-120.3%)
|
| EBIT |
-1.24M
est: 200.0K (-720.7%)
|
-4.54M
est: -1.10M (-312.4%)
|
-4.73M
est: -798.4K (-492.6%)
|
-3.71M
est: -7.34M (+49.5%)
|
-4.02M
est: -3.80M (-5.9%)
|
-3.02M
est: -1.56M (-93.9%)
|
-3.00M
est: 2.30M (-230.3%)
|
-3.24M
est: 4.94M (-165.5%)
|
-1.46M
est: 7.18M (-120.3%)
|
| Net Income |
-723.9K
est: -4.47M (+83.8%)
|
-1.71M
est: -1.10M (-55.1%)
|
-3.57M
est: -798.4K (-347.0%)
|
-2.87M
est: -7.34M (+60.9%)
|
-3.36M
est: -3.62M (+7.1%)
|
-2.00M
est: -262.4K (-660.6%)
|
-2.53M
est: 22.52M (-111.2%)
|
-2.02M
est: 69.81M (-102.9%)
|
-1.45M
est: 111.70M (-101.3%)
|
| SGA |
2.43M
est: 1.29M (+88.2%)
|
3.27M
est: 2.26M (+44.4%)
|
4.35M
est: 1.03M (+320.2%)
|
3.78M
est: 2.20M (+71.7%)
|
2.90M
est: 4.40M (-34.0%)
|
2.27M
est: 3.52M (-35.6%)
|
2.25M
est: 14.87M (-84.9%)
|
1.66M
est: 31.95M (-94.8%)
|
1.35M
est: 46.43M (-97.1%)
|
| EPS |
-0.01
est: -0.02 (+31.7%)
|
-0.03
est: -0.04 (+21.0%)
|
-0.07
est: -0.05 (-52.7%)
|
-0.05
est: -0.05 (-16.1%)
|
-0.06
est: -0.02 (-182.2%)
|
-0.03
est: 0.02 (-258.9%)
|
-0.03
est: 0.11 (-129.4%)
|
-0.02
est: 0.34 (-105.7%)
|
-0.01
est: 0.55 (-101.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Simon Erskine | Chief Development Officer | 186.0K | male |
| David Lionel Brookes FACRRM FAICD MBBS | Executive Chairman & MD | 167.3K | — |
| Jonathan Lindh | Company Secretary | 10.9K | male |
| Hayley van der Meer Biomed Marketing Management | Commercial Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
